Contract terms
Will ET-600 (desmopressin oral solution) launch WAC be ≥ $1,000/month? · v1 (current)
Market metadata
Market
et-600-launch-wac-ge-1000-month-by-2026-03-27
Market ID
6966511aa3e034b36699b527
Rules version
v1
Rules published
Jan 13, 2026, 02:05 PM
Opens
Jan 13, 2026, 02:05 PM
Locks
Mar 27, 2026, 11:59 PM
Resolve-by
—
Measurement
WAC per month
Outcomes
This is a binary market with outcomes YES and NO. If the market is voided, stakes are refunded.
Resolution rules
Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for ET-600 (desmopressin oral solution) is ≥ $1,000/month, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span).
If ET-600 (desmopressin oral solution) does not have an FDA approval for Central diabetes insipidus / AVP-D (as described by sponsor) on or before 2026-03-27, resolves NO.
Reference: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1
Resolution procedure
Probiful admins resolve markets using the criteria above. If multiple sources disagree, admins follow the source hierarchy described in the resolution rules (if present).
Lock time: Mar 27, 2026, 11:59 PM. For “by date” markets, the phrase “on or before” is interpreted as inclusive of the calendar date shown in the contract.
If the market cannot be fairly resolved (e.g., no authoritative sources), it may be voided and stakes refunded.
Sources referenced
Accessed: Mar 26, 2026. This page is a snapshot of rules version v1.